NLRP3 and Alzheimer disease: Other NLRP3 inhibitors in clinical trials at different stages, although not tested in AD, that could represent a possible therapy against neuroinflammation and neurodegenerative disorders include DFV890 (IFM-2427), selnoflast, inzomelid (IZD174), NT-0796, RRX-001, VTX2735, and ZYIL1 [165].